Literature DB >> 17245209

Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics.

Ronnie Fass1.   

Abstract

Nonerosive reflux disease (NERD) and erosive esophagitis are the main presentations of gastroesophageal reflux disease. However, NERD is the most common presentation of gastroesophageal reflux disease in community-based patients. Patients with NERD differ in demographic characteristics from patients with erosive esophagitis, primarily in sex distribution, weight/body mass index, and prevalence of hiatal hernia. Physiologically, patients with NERD tend to have normal lower esophageal sphincter resting pressure, minimal esophageal body motility abnormalities, low esophageal acid exposure profile and minimal nighttime esophageal acid exposure. Patients with NERD have a lower symptom response rate to proton pump inhibitor once daily than patients with erosive esophagitis. Additionally, NERD patients demonstrate a longer lag-time for symptom resolution and lack of difference in symptom response rate between half to full dose proton pump inhibitor as compared with patients with erosive esophagitis.

Entities:  

Mesh:

Year:  2007        PMID: 17245209     DOI: 10.1097/01.mcg.0000225631.07039.6d

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  82 in total

Review 1.  The relationship between gastroesophageal reflux disease and sleep.

Authors:  Ronnie Fass
Journal:  Curr Gastroenterol Rep       Date:  2009-06

2.  Hiatal hernia, lower esophageal sphincter incompetence, and effectiveness of Nissen fundoplication in the spectrum of gastroesophageal reflux disease.

Authors:  Reginald V N Lord; Steven R DeMeester; Jeffrey H Peters; Jeffrey A Hagen; Dino Elyssnia; Corinne T Sheth; Tom R DeMeester
Journal:  J Gastrointest Surg       Date:  2008-12-03       Impact factor: 3.452

Review 3.  Gastrointestinal Complications of Obesity.

Authors:  Michael Camilleri; Harmeet Malhi; Andres Acosta
Journal:  Gastroenterology       Date:  2017-02-10       Impact factor: 22.682

Review 4.  Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis.

Authors:  Florian Rieder; Piero Biancani; Karen Harnett; Lisa Yerian; Gary W Falk
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-03-18       Impact factor: 4.052

Review 5.  Overlap of functional heartburn and gastroesophageal reflux disease with irritable bowel syndrome.

Authors:  Nicola de Bortoli; Irene Martinucci; Massimo Bellini; Edoardo Savarino; Vincenzo Savarino; Corrado Blandizzi; Santino Marchi
Journal:  World J Gastroenterol       Date:  2013-09-21       Impact factor: 5.742

6.  Acid-suppressive effect of rabeprazole 5 mg and 10 mg once daily by 24-hour esophageal pH monitoring in patients with non-erosive reflux disease in Japan: a multicenter, randomized, parallel-group, double-blind pharmacodynamic study.

Authors:  Kiyoshi Ashida; Yoshikazu Kinoshita; Michio Hongo
Journal:  Dig Dis Sci       Date:  2011-02-08       Impact factor: 3.199

7.  GERD: are functional heartburn and functional dyspepsia one disorder?

Authors:  Tiberiu Hershcovici; Ronnie Fass
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-02       Impact factor: 46.802

8.  Functional heartburn, nonerosive reflux disease, and reflux esophagitis are all distinct conditions--a debate: pro.

Authors:  Tomás Navarro-Rodriguez; Ronnie Fass
Journal:  Curr Treat Options Gastroenterol       Date:  2007-08

Review 9.  NERD: an umbrella term including heterogeneous subpopulations.

Authors:  Edoardo Savarino; Patrizia Zentilin; Vincenzo Savarino
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-26       Impact factor: 46.802

10.  Collagen type III alpha I is a gastro-oesophageal reflux disease susceptibility gene and a male risk factor for hiatus hernia.

Authors:  B Asling; J Jirholt; P Hammond; M Knutsson; A Walentinsson; G Davidson; L Agreus; A Lehmann; M Lagerström-Fermer
Journal:  Gut       Date:  2009-04-26       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.